Microsoft PowerPoint - L00 Introduction

214 / 1068

5-FU vs capecitabine
3-year local-regional tumour event rates (11.2% vs 11.8%),
NSABP R-04 establishes
capecitabine as standard of care
03/01/13
5-year DFS (66.4% vs 67.7%)
5-year OS (79.9% vs 80.8%);